CONSHOHOCKEN, Pa. - Tuesday, 13. August 2024 AETOSWire 

Growing revenue by more than 78% in three years, Boomi makes prestigious list of fastest-growing companies in the nation

(BUSINESS WIRE) -- Boomi™, the intelligent integration and automation leader, today announced its inclusion in the annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. The list provides a data-driven look at the most successful companies within the economy’s most dynamic segments.

“Being named to the Inc. 5000 list is an honor and a testament to not only our rapid growth but also the increasing demand for our innovative integration and automation platform,” said Steve Lucas, CEO at Boomi. “As organizations strive to navigate the complexities of digital transformation, Boomi’s leadership in AI, automation, API management, and intelligent integration sets us apart in the industry and t ... Read more »

AMSTERDAM & BENGALURU, India 
LTTS to provide Integrated Engineering Design and Procurement Services for Shell’s global assets in multi-year pact
(BUSINESS WIRE) -- L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in engineering, digital and R&D services, announced that it has signed a long-term framework agreement with Shell, one of the world's largest energy companies.

The multi-year framework agreement will see LTTS providing Integrated Engineering and Procurement Services along with Digital Engineering Services, Data Governance for Capital Projects and Digital Project Management Consultancy for Shell’s global assets as necessary.

With over two decades of experience in engineering, manufacturing services, digital transformation, and data services, LTTS is positioned well to support Shell on a global scale deploying their unique global delivery model for delivering projects.

Amit Chadha, ... Read more »

ZUG, Switzerland - Tuesday, 13. August 2024

Ad hoc announcement pursuant to Art. 53 LR 

Nemluvio® (nemolizumab) is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in prurigo nodularis1-3
Prurigo nodularis is a chronic skin condition that is estimated to affect up to 181,000 people in the United States, and is characterized by persistent, intense itch4-8
The U.S. Food and Drug Administration granted Nemluvio Priority Review for the treatment of prurigo nodularis in February 2024, following its Breakthrough Therapy Designation in 2019
Further marketing authorization applications are under regulatory review by multiple regulatory authorities, including the European Medicines Agency and Health Canada
 

(BUSINESS WIRE) -- Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemo ... Read more »

COSTA MESA, Calif. - Tuesday, 13. August 2024 AETOSWire 
The combined offerings deliver the power of behavioral analytics with Experian’s extensive fraud detection capabilities to combat AI-enabled fraud

(BUSINESS WIRE)--Experian® — the global data and technology company — announced today that it has acquired NeuroID, an industry leader in behavioral analytics. NeuroID’s modern and frictionless capabilities amplify Experian’s fraud risk suite by providing a new layer of insight into digital behavioral signals and analytics observed for both new and returning users throughout the customer lifecycle, including account openings, logins and transactions.

NeuroID’s behavioral analytics solutions are available now through CrossCore® on the Experian Ascend Technology Platform™ as a key fraud-detection capability. Experian’s identity verification and fraud prevention solutions helped clients av ... Read more »